• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

口腔颌面部非霍奇金淋巴瘤的临床病理特征及预后:369例分析

[Clinicopathological characteristics and prognosis of non-Hodgkin lymphoma in oral and maxillofacial regions: An analysis of 369 cases].

作者信息

Su Q, Peng X, Zhou C X, Yu G Y

机构信息

Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology & National Center of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of Oral Biomaterials and Digital Medical Devices & Beijing Key Laboratory of Digital Stomato-logy & NHC Research Center of Engineering and Technology for Computerized Dentistry & NMPA Key Laboratory for Dental Materials, Beijing 100081, China.

Department of Oral Pathology, Peking University School and Hospital of Stomatology & National Center of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of Oral Biomaterials and Digital Medical Devices & Beijing Key Laboratory of Digital Stomato-logy & NHC Research Center of Engineering and Technology for Computerized Dentistry & NMPA Key Laboratory for Dental Materials, Beijing 100081, China.

出版信息

Beijing Da Xue Xue Bao Yi Xue Ban. 2023 Feb 18;55(1):13-21. doi: 10.19723/j.issn.1671-167X.2023.01.003.

DOI:10.19723/j.issn.1671-167X.2023.01.003
PMID:36718684
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9894798/
Abstract

OBJECTIVE

To investigate the clinicopathological characteristics and factors influencing the prognosis of non-Hodgkin lymphoma (NHL) in oral and maxillofacial regions.

METHODS

Clinicopathological data of 369 patients with oral and maxillofacial NHL initially diagnosed in Peking University Hospital of Stomatology from 2008 to 2020 were collected and analyzed retrospectively.

RESULTS

There were 180 males and 189 females. The median age of the patients was 56 years (3 months to 92 years), and the median duration was three months. Clinically, 283 cases manifested as mass, 38 cases as ulcerative necrotizing lesions, and 48 cases as diffuse soft tissue swelling. The lesions of 90 cases located in face and neck (75 cases neck, 20.3%), 99 cases were of major salivary glands (79 cases parotid glands, 20.9%), 103 cases of oral cavity, 50 cases of maxillofacial bones, 20 cases of Waldeyer's ring, and 7 cases of infratemporal fossa. In the study, 247 of the 369 patients had cervical lymphadenopathy, only 40 cases had B symptoms, and 23 cases had the bulky disease. Of the 369 NHLs, 299 (81%) were B-cell NHL, and 70(19%) were T-cell NHL. Diffuse large B-cell lymphoma, extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, follicular lymphoma, and extranodal natural killer (NK)/T-cell lymphoma nasal type were the most common pathological subtypes. According to Ann Arbor staging, 87, 138, 106, and 38 cases were classified as staged Ⅰ, Ⅱ, Ⅲ, Ⅳ, respectively. The me-dian follow-up time was 48 months, 164 patients died during the follow-up period. The overall survival rates for one year, two years, and five years were 90.1%, 82.4%, and 59.9%, respectively, and the median survival was (86.00±7.98) months. Multivariate analysis showed that age ( < 0.001), Ann Arbor staging ( < 0.001), elevated lactate dehydrogenase (=0.014), and pathological subtype (=0.049) were the independent factors influencing the overall survival rate of NHL patients.

CONCLUSION

Oral and maxillofacial NHL has unique clinical characteristics and distribution patterns of pathological subtypes. Fewer patients had systemic symptoms. Neck and parotid glands were the most common sites invaded by NHL. Advanced age, Ann Arbor stage Ⅲ-Ⅳ, B symptoms, and T-cell NHL may predict a poor prognosis in oral and maxillofacial NHL patients.

摘要

目的

探讨口腔颌面部非霍奇金淋巴瘤(NHL)的临床病理特征及影响预后的因素。

方法

回顾性收集并分析2008年至2020年在北京大学口腔医院初诊的369例口腔颌面部NHL患者的临床病理资料。

结果

男性180例,女性189例。患者中位年龄56岁(3个月至92岁),中位病程3个月。临床上,283例表现为肿块,38例为溃疡性坏死性病变,48例为弥漫性软组织肿胀。90例病变位于面颈部(颈部75例,占20.3%),99例位于大唾液腺(腮腺79例,占20.9%),103例位于口腔,50例位于颌面部骨,20例位于咽淋巴环,7例位于颞下窝。本研究中,369例患者中有247例有颈部淋巴结肿大,仅40例有B症状,23例有大包块病变。369例NHL中,299例(81%)为B细胞NHL,70例(19%)为T细胞NHL。弥漫性大B细胞淋巴瘤、黏膜相关淋巴组织结外边缘区B细胞淋巴瘤、滤泡性淋巴瘤和结外鼻型自然杀伤(NK)/T细胞淋巴瘤是最常见的病理亚型。根据Ann Arbor分期,Ⅰ、Ⅱ、Ⅲ、Ⅳ期分别为87例、138例、106例和38例。中位随访时间为48个月,随访期间164例患者死亡。1年、2年和5年总生存率分别为90.1%、82.4%和59.9%,中位生存期为(86.00±7.98)个月。多因素分析显示,年龄(<0.001)、Ann Arbor分期(<0.001)、乳酸脱氢酶升高(=0.014)和病理亚型(=0.049)是影响NHL患者总生存率的独立因素。

结论

口腔颌面部NHL具有独特的临床特征和病理亚型分布模式。有全身症状的患者较少。颈部和腮腺是NHL最常侵犯的部位。高龄、Ann Arbor分期Ⅲ - Ⅳ期、B症状和T细胞NHL可能预示口腔颌面部NHL患者预后不良。

相似文献

1
[Clinicopathological characteristics and prognosis of non-Hodgkin lymphoma in oral and maxillofacial regions: An analysis of 369 cases].口腔颌面部非霍奇金淋巴瘤的临床病理特征及预后:369例分析
Beijing Da Xue Xue Bao Yi Xue Ban. 2023 Feb 18;55(1):13-21. doi: 10.19723/j.issn.1671-167X.2023.01.003.
2
[Clinicopathological features and possible prognostic factors in parotid lymphomas].[腮腺淋巴瘤的临床病理特征及可能的预后因素]
Beijing Da Xue Xue Bao Yi Xue Ban. 2019 Feb 18;51(1):35-42. doi: 10.19723/j.issn.1671-167X.2019.01.007.
3
Localized B-cell non-Hodgkin's lymphoma of oral cavity and maxillofacial region: a clinical study.口腔颌面部局限性B细胞非霍奇金淋巴瘤:一项临床研究。
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Mar;99(3):303-10. doi: 10.1016/j.tripleo.2004.03.028.
4
Extranodal non-hodgkin lymphomas of the oral cavity and maxillofacial region: a clinical study of 58 cases and review of the literature.口腔颌面部结外非霍奇金淋巴瘤:58例临床研究及文献复习
J Oral Maxillofac Surg. 2012 Dec;70(12):2776-85. doi: 10.1016/j.joms.2012.01.018. Epub 2012 Apr 10.
5
Clinical characteristics, pathological distribution, and prognostic factors in non-Hodgkin lymphoma of Waldeyer's ring: nationwide Korean study.瓦尔代尔环非霍奇金淋巴瘤的临床特征、病理分布及预后因素:韩国全国性研究
Korean J Intern Med. 2014 May;29(3):352-60. doi: 10.3904/kjim.2014.29.3.352. Epub 2014 Apr 29.
6
Clinical characteristics and prognostic analysis of primary extranodal non-Hodgkin lymphoma of the head and neck.头颈部原发性结外非霍奇金淋巴瘤的临床特征及预后分析。
Aging (Albany NY). 2024 Apr 5;16(8):6796-6808. doi: 10.18632/aging.205726.
7
Non-Hodgkin lymphoma of the Waldeyer's ring: clinicopathologic and therapeutic issues.瓦尔代尔环非霍奇金淋巴瘤:临床病理及治疗问题
Leuk Lymphoma. 2008 Dec;49(12):2263-71. doi: 10.1080/10428190802493686.
8
[A clinicopathological analysis of gastric lymphoma].[胃淋巴瘤的临床病理分析]
Zhonghua Bing Li Xue Za Zhi. 2005 Jun;34(6):332-6.
9
[Clinicopathological features and prognostic analysis of 151 patients with primary extra-nodal non-Hodgkin's lymphoma].151例原发性结外非霍奇金淋巴瘤的临床病理特征及预后分析
Zhonghua Zhong Liu Za Zhi. 2014 Nov;36(11):858-62.
10
Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in the oromaxillofacial head and neck region: A retrospective analysis of 105 patients.口颌面部头颈部黏膜相关淋巴组织结外边缘区 B 细胞淋巴瘤:105 例回顾性分析。
Cancer Med. 2020 Jan;9(1):194-203. doi: 10.1002/cam4.2681. Epub 2019 Nov 15.

本文引用的文献

1
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
2
Cancer Statistics, 2021.癌症统计数据,2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
3
International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI.弥漫性大 B 细胞淋巴瘤的国际预后指数:IPI、R-IPI 和 NCCN-IPI 的比较。
Blood. 2020 Jun 4;135(23):2041-2048. doi: 10.1182/blood.2019002729.
4
Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making.在现代化疗时代,列线图修订风险指数的验证及其与其他模型在结外鼻型 NK/T 细胞淋巴瘤中的比较:预后和临床决策的指征。
Leukemia. 2021 Jan;35(1):130-142. doi: 10.1038/s41375-020-0791-3. Epub 2020 Mar 9.
5
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.NCCN 指南解读:B 细胞淋巴瘤,第 3.2019 版。
J Natl Compr Canc Netw. 2019 Jun 1;17(6):650-661. doi: 10.6004/jnccn.2019.0029.
6
Diagnosis and classification of lymphoma: Impact of technical advances.淋巴瘤的诊断和分类:技术进步的影响。
Semin Hematol. 2019 Jan;56(1):30-36. doi: 10.1053/j.seminhematol.2018.05.007. Epub 2018 May 29.
7
Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.全球癌症生存趋势监测 2000-14 年(CONCORD-3):对来自 71 个国家 322 个基于人群的登记处的 37513025 名诊断患有 18 种癌症之一的患者的个体记录进行分析。
Lancet. 2018 Mar 17;391(10125):1023-1075. doi: 10.1016/S0140-6736(17)33326-3. Epub 2018 Jan 31.
8
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience.利妥昔单抗治疗B细胞血液系统恶性肿瘤:20年临床经验回顾
Adv Ther. 2017 Oct;34(10):2232-2273. doi: 10.1007/s12325-017-0612-x. Epub 2017 Oct 5.
9
Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.用于治疗非霍奇金淋巴瘤的维布妥昔单抗:一项系统评价。
Crit Rev Oncol Hematol. 2017 Jan;109:42-50. doi: 10.1016/j.critrevonc.2016.11.009. Epub 2016 Nov 21.
10
[Clinical Characteristics,Treatment Strategies and Prognostic Factors of 254 Cases of Non Hodgkin's Lymphoma].254例非霍奇金淋巴瘤的临床特征、治疗策略及预后因素
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Aug;24(4):1044-50. doi: 10.7534/j.issn.1009-2137.2016.04.016.